- Home
- ABUS vs QNST Comparison
ABUS vs QNST Comparison
Compare ABUS & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABUS | QNST |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.5M | 870.0M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | ABUS | QNST |
|---|---|---|
| Price | $4.17 | $11.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $24.75 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 03-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | $14,606,000.00 | ★ $1,105,594,000.00 |
| Revenue This Year | $125.30 | $14.29 |
| Revenue Next Year | N/A | $14.88 |
| P/E Ratio | ★ N/A | $10.73 |
| Revenue Growth | ★ 116.64 | 19.05 |
| 52 Week Low | $2.71 | $10.29 |
| 52 Week High | $5.10 | $23.24 |
Technical Indicators
Market Signals| Indicator | ABUS | QNST |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 35.05 |
| Support Level | $3.85 | $10.29 |
| Resistance Level | $4.26 | $14.40 |
| Average True Range (ATR) | 0.33 | 0.98 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 58.18 | 20.48 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.